deep vein thrombosis: a less noticed complication in hematologic malignancies and immunologic disorders

Deep vein thrombosis (dvt) is a common complication in hematologic malignancies and immunologic disorders that coagulation and inflammatory factors play a crucial role in its occurrence. the content used in this article has been obtained by pubmed database and google scholar search engine of english-language articles (1980–2019) using the “deep vein thrombosis,” “hematologic malignancies,” “immunologic disorders” and “treatment.” increased levels of coagulation factors, the presence of genetic disorders, or the use of thrombotic drugs that stimulate coagulation processes are risk factors for the development of dvt in patients with hematologic malignancies. inflammatory and auto-anti-inflammatory factors, along with coagulant factors, play an essential role in the formation of venous thrombosis in patients with immunological disorders by increasing the recruitment of inflammatory cells and adhesion molecules. therefore, anti-coagulants in hematologic malignancies and immunosuppressants in immune disorders can reduce the risk of developing dvt by reducing thrombotic and inflammatory activity. considering the increased risk of dvt due to impaired coagulation and inflammation processes, analysis of coagulation and inflammatory factors have prognostic values in patients with immunologic deficiencies and hematologic malignancies. evaluation of these factors as diagnostic and prognostic biomarkers in the prediction of thrombotic events could be beneficial in implementing effective treatment strategies for dvt.